SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?


To: Steve Lokness who wrote (250)1/10/2007 5:26:22 PM
From: Mike McFarland  Read Replies (2) | Respond to of 360
 
Well, that is the dogma, that glgc has
lousy management--they blew through 300M.
So what really? How much does Pfizer blow
through with their R&D? Biotech is expensive.
I have not made any real money in biotech
stocks since '99-2000, and part of the reason
is that the sector is not profitable and it
is extremely hard to sort the wheat from the
better wheat. And part of the time the chaff
stocks are the best ones to be trading, ha!
(Stem cells always...drives you crazy.)
There are stem cell stocks without a prayer
that have valuations quite a bit greater than,
for instance, Gene Logic. And GLGC has been
right there all along--just hasn't had anything
to hype. Drudge work--toxicogenomics? Nobody
buys that stock.

GLGC is a lot like Celera, it looked good
at first, but genomic data became a commodity
item. And it really didn't make sense to
share your data to begin with!

Perlegen and the big pharmas involved in the HapMap:
Same thing, everbody wants in, I assume Perlegen is
there because they want to be taken seriously--but
is sharing SNP maps going to be profitable? Wouldn't
you really want to be the only one with the map?

Anyway, getting back to Gene Logic--are they really
incompetent? Of course not, that is just the dogma
that goes along with the valuation. From that article
at dddmag, here is a snp of the stuff they do:

Using our central nervous system database, we found that in male individuals with and without major depression who committed suicide, spermine/spermidine N(1)-acetyltransferase (SSAT) the rate-limiting enzyme in the catabolism of polyamines, was down-regulated in three different brain regions. Gene expression data was confirmed by RT-PCR, immunohistochemistry, and Western blot analyses. Furthermore, a single nucleotide polymorphism (SNP) variant located in the SSAT polyamine-responsive element regulatory region (SSAT342A/C) showed a significant effect of genotype on brain SSAT gene expression levels—the 342A allele was associated with increased transcript expression. Upon further investigation of this variant in blood from an independent sample of 181 male suicide completers and 80 male controls, we found a higher frequency of the 342C allele among suicide cases (odds ratio, 2.7; 95% confidence interval, 1.4-5.3; P = .005), indicating that this allele appears to increase predisposition to suicide. These data suggest a role for SSAT in suicide and depression and a role for the SSAT342 locus in the regulation of SSAT gene expression. Thus, the SSAT342 locus is a potential biomarker to discern individuals at higher risk to commit suicide.

Well, that sounds like pretty typical biotech, probably
not a lot different from what the scientists at Pfizer
do. Is there money in it? Can't say, but the stock is
cheap so I have some shares. I don't actually expect to
make money on biotech. Anadys was a nice gift last year,
a great trade and the only good trade I've made since 2000.
I probably have one or two good trades in me before I
give up following biotech. GLGC isn't probably one of them,
but it is very nice to play along, biotech stocks have
been a lot of fun. Next year I might finally move to a
different sector. Maybe Oil? Peace in Iraq and $20 barrel
wont be far behind <g>.